Sunshine BiopharmavsThermo Fisher Scientific

SBFM and TMO stock compared: price, dividend, valuation and results, from SEC filings.

SBFM

Sunshine Biopharma Inc.

$2.70

Value $2.2M

-4.93%
SBFM's page

TMO

Thermo Fisher Scientific Inc

$700.22

Value $260B

+0.11%
TMO's page

Sunshine Biopharma (SBFM) has a market value of $2.2M and Thermo Fisher Scientific (TMO) $260B. Over the last year, with dividends, SBFM moved -99.2% and TMO +19.5%. Dividend yield: SBFM none, TMO 0.26%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    SBFM$2.2M

    TMO$260B

    TMO is 116,951 times SBFM

  • Revenue, 12 months

    SBFM$35M

    TMO$47.4B

    TMO is 1,339 times SBFM

  • Net income, 12 months

    SBFM-$6.2M

    TMO$7.1B

  • Operating margin

    SBFM-17.2%

    TMO17.9%

    35.1 points apart

  • ROIC

    SBFM-19.3%

    TMO8.2%

    27.4 points apart

  • P/E

    SBFM–

    TMO36.8

  • Dividend yield

    SBFM0.0%

    TMO0.3%

    0.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

SBFM-100.0%

TMO+58.8%

050100150202420252026
Returns by period
PeriodSBFMWith dividendsTMOWith dividends
1 year since November 12, 2025-99.2%Price -99.2%+19.5%Price +19.1%
3 years since November 13, 2023-100.0%-97.0% a yearPrice -100.0%+58.8%+16.7% a yearPrice +57.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

SBFMSunshine BiopharmaTMOThermo Fisher Scientific

Valuation

SBFMTMO
Valuation
Price$2.70$700.22
Market value$2.2M$260B
Enterprise value (EV)–$295B
P/E–36.8
P/E, 5-year median–32.7
P/B0.14.8
EV/EBIT–34.9
Free cash flow yield–2.9%

Results and growth

SBFMTMO
Results and growth
Revenue, 12 months$35M$47.4B
Net income, 12 months-$6.2M$7.1B
Free cash flow, 12 months-$6.0M$7.6B
Earnings per share, 12 months-$170.83$18.96
Revenue growth, year on year4.1%3.9%
Revenue growth a year, past+247.7%over 5 years+6.7%over 5 years
EPS growth a year, past–+2.1%over 5 years

Margins and returns on capital

SBFMTMO
Margins and returns on capital
Gross margin30.4%–
Operating margin-17.2%17.9%
Net margin-17.5%14.9%
ROIC-19.3%8.2%
ROE-24.7%13.4%

Balance sheet

SBFMTMO
Balance sheet
Cash$15M$6.1B
Total debt$627.6K$41.4B
Net debt / EBITDA–3.7
Interest cover–5.5×

Dividends and buybacks

SBFMTMO
Dividends and buybacks
Dividend yield–0.3%
Dividend per share, 12 months–$1.84
Dividend growth a year, past–+14.3%over 5 years
Buyback yield–1.2%
Shareholder yield–1.4%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: SBFM or TMO

Didn't find what you were looking for?

Ask us
Which is bigger, Sunshine Biopharma or Thermo Fisher Scientific?

By market value, Thermo Fisher Scientific ($260B) is about 116,951.0 times Sunshine Biopharma ($2.2M), at today's prices.

How did SBFM and TMO stock do over the last 3 years?

Since November 13, 2023, SBFM's price moved -100.0% and TMO's +57.3%. With dividends: SBFM -100.0% (-97.0% a year), TMO +58.8% (+16.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, SBFM or TMO?

The dividend yield at today's price is none for Sunshine Biopharma and 0.26% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.

Which has the higher profit margins, Sunshine Biopharma or Thermo Fisher Scientific?

Over the last twelve months, the net margin was -17.5% for Sunshine Biopharma and 14.9% for Thermo Fisher Scientific, and the operating margin -17.2% and 17.9%. Revenue was $35M and $47.4B.

Which is the better investment, Sunshine Biopharma or Thermo Fisher Scientific?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.